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Neuroscience has progressed dramatically 
since the time of Ramon y Cajal in 1894, 
and the advancement of technologies, such 
as microscopy, molecular biology, electro-
physiology, as well as breakthroughs in bio-
chemistry and cognitive science all aided 
in the evolution of neuroscience. As physi-
cians continue to understand and diagnose 
neuronal diseases, scientists have diligently 
worked side-by-side to discover and develop 
innovative drugs as well as other alternative 
treatments.
Therefore, we at Gene Expression Systems, 
Inc.,  and  Appasani  Research  Conferences 
decided to join together an array of speak-
ers,  including  tenured  professors,  junior 
faculty members, postdoctoral fellows from 
academia,  as  well  as  entrepreneurs  from 
venture backed neurodiscovery-based bio-
tech companies and experienced executives 
from  the  pharmaceutical  sector  to  main-
tain the motto of “Bridging Academia and 
Industry.”
The Neuron to Synapse-2010 Meeting 
took place at the Holiday Inn Midtown in 
New York City, NY, USA, on June 7–8, 2010. 
An ideal location for the growing number 
of  neuroscience  laboratories;  about  60 
members of academia and industry gath-
ered for 2 days of lectures on novel research 
techniques,  new  therapeutics,  and  drug 
development underway in the drastically 
growing field.
The keynote opening lecture was given 
by Dr. Robert Darnell of The Rockefeller 
University.  Through  the  development 
of  a  novel  technique,  high-throughput 
sequencing of RNA isolated by crosslink-
ing  immunoprecipitation  (HITS-CLIP), 
Dr. Darnell described how his lab is gen-
erating maps of RNA–protein interactions 
in living tissues to better understand how 
RNA regulation goes awry in human brain 
disease and cancer; specifically focusing 
on  paraneoplastic  neurologic  disorders 
(PNDs). For his contributions to the field 
of neuroscience and upholding the true val-
ues of the role as a physician-  scientist, the 
scientific committee presented Dr. Darnell 
with the “Physician-Scientist of the Year 
Award.” This session on the “Neurobiology 
of Human Brain Diseases” continued with 
presentations from Dr. Ottavio Arancio of 
Columbia University who introduced the 
idea of amyloid-beta impairing memory 
in Alzheimer’s disease. This presentation 
was followed up by Dr. Patrick May of 
Lilly Research Labs who presented new 
developments in secretase inhibitors for 
the treatment of Alzheimer’s disease. Next, 
Dr.  Paul  Lombroso  of  Yale  University 
presented  his  discovery  of  the  mol-
ecule Striatal Enriched Protein Tyrosine 
Phosphatase (STEP) and his new novel 
treatments underway to improve cogni-
tion in Alzheimer’s patients. Another talk 
was given by Dr. Shin-Ya Kawaguchi of 
the  Kyoto  University  (Japan)  in  which 
he  described  a  biophysical  approach  to 
studying the systems biology of plasticity 
at inhibitory synapses. The session ended 
with a final talk by Dr. Aiden Corvin of 
Trinity College Dublin in which he pre-
sented novel techniques to understanding 
the mechanism of schizophrenia etiology 
from genomic lessons.
The afternoon keynote session was given 
by Dr. Joseph LeDoux who was presented 
with the “Neuron Innovator Award” for his 
enormous research in determining the bio-
logical mechanisms of emotional memory. 
This  session  on  “Learning  &  Memory” 
continued with a talk by Dr. Yi Zhong of 
Cold Spring Harbor Laboratory in which 
he  described  memory  development  in 
Drosophila  and  his  lab’s  novel  approach 
to  control “forgetting.”  Next,  Dr.  Robert 
Hawkins of Columbia University presented 
work on the role of spontaneous transmit-
ter  release  in  learning-related  synaptic 
plasticity. The session ended with a talk by 
Dr. Lila Davachi of New York University 
who described work performed in her lab 
using fMRI technology to understand the 
mechanisms  of  memory  formation  and 
“forgetting”.
The final session of the day ended with 
three talks by Dr. Songhai Shi of Memorial 
Sloan Kettering Cancer Centre, Dr. Stewart 
Anderson of Weill Cornell Medical College 
(New  York  City),  and  Dr.  Ian  Scott  of 
Accucela, Inc. These speakers all presented 
their work on neuronal circuits and cortical 
migration in the mammalian neocortex.
The second day of the conference opened 
with  a  session  on  Neuro-developmental 
and psychiatric disorders. The first talk was 
given by Dr. Eric Nestler of the Mount Sinai 
School of Medicine in which he described 
novel techniques his lab is using to discover 
the epigenetic mechanisms of drug addic-
tion. Next, Dr. Joan Fallon of Curemark, 
Inc., gave an industry keynote lecture on 
new  drug  developments  and  therapeu-
tics  that  her  company  is  developing  for 
the  treatment  of  autism  and  disorders 
in  the  autistic  spectrum.  Following  this 
lecture, Dr. Wenzhen Duan of the Johns 
Hopkins  University  presented  her  labs 
work on potential therapeutic targets for 
Huntington’s disease. Dr. Alistair Stewart 
next described phase 2 clinical trials being 
done at Allon Therapeutics, Inc., for the 
treatment of Alzheimer’s disease and fron-
to-temporal dementia. This lecture was fol-
lowed up by a presentation by Dr. Youming 
Lu  of  Louisiana  University  in  which  he 
described the role of NMDA receptor cell 
death  signals  at  extra-synaptic  sites.  Dr. 
Christian Thomsen then described research 
being done at Lundbeck Research on the 
role of neuroprotective mechanisms in the 
treatment of Parkinson’s disease. The ses-
sion ended with a final presentation by Dr. 
David Bloom of the University of Florida 
on the use of viral vectors to restore hip-
pocampal synaptic function in Fragile X 
Syndrome using a rodent model.
The final session of the day – and of the 
conference – ended with five talks on ther-
apeutics for neurodegenerative diseases. 
Dr. Dani Brunner gave a wonderful over-
view of the various treatments and ther-
apeutics underway at Psychogenics, Inc. 
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of the Yale University School of Medicine, 
and Dr. Eric J. Nestler of the Mount Sinai 
School of Medicine. We would also like to 
offer our thanks to all of our sponsors as 
well as the Appasani Research Conferences 
Organization.
We also like to invite all members of the 
Frontiers community and members of the 
Neuroscience field to attend our upcom-
ing European Neurodegenerative Diseases 
Meeting at the University of Oxford (UK) 
on September 20–21, 2010.
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Next, Dr. Amy Arnsten of Yale University 
described her novel technique on rescuing 
prefrontal cortical grey matter in various 
neuropsychiatric  illnesses.  Dr.  Kenneth 
Rhodes next gave an overview of thera-
peutics  currently  underway  at  Biogen 
Idec. The final lecture of the conference 
was given by Dr. Wei-Qin Zhao of Merck 
Research Laboratories on Aβ oligomer-
induced  synaptic  loss  via  calcineurin-
mediated endocytosis.
Our primary goal for publicizing this con-
ference was to exemplify the possibilities for 
cross-fertilization of scientific knowledge. 
The main focus of Gene Expression Systems, 
Inc., is to bring together members of industry 
and academia to one central location where 
collaborations can be made to give rise to 
the development of new therapeutics and 
drugs. By holding various   meetings on the 
hot topics of the scientific world, we hope to 
continue to aid in the growth of translational 
medicine. We are grateful to the members of 
the scientific committee: Dr. Paul Lombroso 